

locations, pursuant to the Sequence Listing requirements. As there are 42 sequences in the present application, the nature of the amendments to the specification were sufficiently extensive that it was considered expedient to prepare a substitute specification. Consequently, also attached to the present amendment is a substitute specification, both in clean form and in "red-line" form, the latter showing the nature of the amendments to the specification relative to the original specification.

It is believed that this paper complies with the requirements set forth in the Notification of Missing Requirements mailed September 20, 2001, such that the application is now in condition for examination on the merits. Such action is respectfully requested.

Attached hereto is a marked-up version of the changes made to the claims. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

Respectfully submitted,

YOUNG & THOMPSON

*Philip A. DeBor*

Arg. no.  
50,696

By

*for*  
\_\_\_\_\_  
Andrew J. Patch  
Attorney for Applicant  
Registration No. 32,925  
745 South 23rd Street  
Arlington, VA 22202  
Telephone: 521-2297

November 13, 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Claim 2 has been amended as follows:

2. (amended) A sequence according to claim 1, wherein the sequence that encodes for apopholasin is as shown in Figure 4B (SEQ ID NO: 1).

Claim 3 has been amended as follows:

3. (amended) A sequence according to claim 1, wherein the sequence that encodes for apopholasin is as shown in any one of Figures 1, 2, 3, 4A, 6 or 9 (encompassing SEQ ID NOS 1-6 and 23).

Claim 12 has been amended as follows:

12. (amended) An isolated, purified or recombinant polypeptide according to claim 11 comprising the amino acid sequence of Figure 4 or Figure 5 (SEQ ID NOS 1 and 4-6).